In this Practice Point commentary, we discuss the findings and limitations of a randomized, placebo-controlled trial conducted by Lewis and colleagues that examined the efficacy of rosiglitazone for the treatment of patients with mild-to-moderately active ulcerative colitis. The results show that rosiglitazone had superior efficacy to placebo for inducing clinical response and remission. However, the efficacy of rosiglitazone in this setting was modest. We believe that this finding might be attributable to the high numbers of patients included in the trial who were refractory to conventional therapy. Rosiglitazone might be more effective if combined with 5-aminosalicylic acid therapy and used in patients with less-refractory disease. We highlight the issues to consider when interpreting and generalizing these findings to clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ncpgasthep1226 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review.
Nutrients
November 2024
Department of Pediatric Diabetes, Clinical Auxology and Obesity, Poznan University of Medical Sciences, 60-572 Poznan, Poland.
: Childhood obesity is an epidemic and a significant health concern all over the world. Several factors can influence excess weight gain, including eating behaviors, physical inactivity, and genetics. Children and adolescents with obesity have a four-times greater risk of developing type 2 diabetes (T2D) compared with their normal-weight peers.
View Article and Find Full Text PDFIntegrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity.
Metabolomics
December 2024
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Article Synopsis
- Thiazolidinediones (TZDs), like pioglitazone and rosiglitazone, are effective for treating type II diabetes but raise concerns about their role in heart failure risk, creating safety uncertainties that limit their use.
- This study employed a multi-omics approach to explore the mechanisms behind TZD-induced heart toxicity, revealing significant alterations in biochemical pathways related to energy metabolism and a shift towards anaerobic glycolysis in heart cells.
- Findings highlighted disruptions in the glutathione system and identified specific amino acid signatures linked to heart failure, suggesting these could be useful for early detection of TZD-related cardiotoxicity and potential therapeutic targets in the future.
Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, 824236, India.
Thiazolidinedione derivatives have shown significant potential as targeted cancer therapies by leveraging their various mechanisms of action. These include suppressing cell proliferation, triggering apoptosis, and influencing signaling pathways associated with tumor development. Their multifaceted effects make them promising candidates for advancing cancer treatment strategies.
View Article and Find Full Text PDFEnhanced Neuroprotection in Experiment Multiple Sclerosis through Combined Rosiglitazone and Probiotic-Loaded Solid Lipid Nanoparticles: Modulation of Cellular Signaling Pathways.
CNS Neurol Disord Drug Targets
November 2024
SRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh, 201204, India.
Background: Multiple sclerosis (MS) is a persistent autoimmune condition characterized by inflammation and neurodegeneration. The current efficacy of treatments is limited, which has generated interest in developing neuroprotective strategies. Solid lipid nanoparticles (SLNs) and probiotics are potential drug delivery vehicles for targeting the CNS (Central nervous system), regulating immune responses, and supporting neuroprotection in neurological conditions.
View Article and Find Full Text PDFAgonists of the Nuclear Receptor PPARγ Can Produce Biased Signaling.
Mol Pharmacol
November 2024
Biochemistry and Biophysics Graduate Program (M.L.R., T.S.H.), Department of Biomedical and Pharmaceutical Sciences (M.D.N., T.S.H.), and Pharmaceutical Sciences and Drug Design Graduate Program (A.H.V., T.S.H.), University of Montana, Missoula, Montana
Biased signaling and ligand bias, often termed functional selectivity or selective nuclear receptor modulation, have been reported for nuclear receptor partial agonists over the past 20 years. Whether signaling differences produced by partial agonists result from less intense modulation, off-target effects, or biased signaling remains unclear. A commonly postulated mechanism for biased signaling is coactivator favoritism, where agonists induce different coactivator recruitment profiles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!